Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease
about
Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane VesiclesCrosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: a recipe for impaired wound healingThe stem cell secretome and its role in brain repair.Stem cell therapy in neurodegenerative diseases: From principles to practice.Stem cells for cell replacement therapy: a therapeutic strategy for HD?Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of ratsMesenchymal Stem Cells from Human Extra Ocular Muscle Harbor Neuroectodermal Differentiation Potential.Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.Translational research in Huntington's disease: opening up for disease modifying treatmentFluorescence imaging of in vivo miR-124a-induced neurogenesis of neuronal progenitor cells using neuron-specific reporters.Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector.Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.Stem cells in canine spinal cord injury--promise for regenerative therapy in a large animal model of human disease.Mesenchymal stem cells as a potential therapeutic tool for spinocerebellar ataxia.Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.Consequences of brain-derived neurotrophic factor withdrawal in CNS neurons and implications in disease.Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells.Mesenchymal stem cells ameliorate cerebellar pathology in a mouse model of spinocerebellar ataxia type 1.Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neuronsStem cell models of polyglutamine diseases and their use in cell-based therapies.Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal FibrosisThe Complex Ethics of First In Human Stem Cell Clinical Trials.Mesenchymal stem cell therapy in nonhematopoietic diseases.Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.A New Chapter for Mesenchymal Stem Cells: Decellularized Extracellular Matrices.Mesenchymal stem cells attenuate peripheral neuronal degeneration in spinocerebellar ataxia type 1 knockin mice.Morphological and Functional Attenuation of Degeneration of Peripheral Neurons by Mesenchymal Stem Cell-Conditioned Medium in Spinocerebellar Ataxia Type 1-Knock-in Mice.
P2860
Q26767270-C6480695-FBCB-4822-9D60-D6ECA1981E2CQ33690017-B6F0D098-C5DC-4BCF-BC0F-0CE5D45B5085Q33771698-9BE680C9-9F59-440D-9D16-1A46218591C5Q34997944-FAFA321D-8953-4084-8BF4-8D0E29E4F61FQ35250495-94D6F902-A16B-4D42-819B-7AB767D90C47Q35949645-39057335-3147-4BE6-9360-AF3AE1455B60Q36036209-A4BBA1FD-A5CE-448A-895B-F82EEC97F28DQ36162423-A8B941A6-2091-4BF9-91E0-0273AD5B32CBQ36722683-808C4EC8-A6CC-4143-AE69-E12DB9E37C77Q36840350-E9D0B932-3723-42DC-9223-DC939B10F5DEQ36939755-DB8A1084-F644-4CE0-8B54-94092615F56AQ37170654-7590ECE0-EAA1-4DA2-AFCF-ED8EE60814DFQ37652595-50FE35BF-283E-475C-81A4-D6FCAA2A0688Q38181868-FF6C9739-E267-4790-89C4-31C423DBEEA5Q38244902-2E7B7758-13FF-4068-9E6A-5A8B154903D1Q38256491-BD2B5AD4-6DFA-4911-840B-21C220DA4C7AQ38462208-0B6054FF-92C8-4E25-85F2-5986ABE38709Q38789148-3FEDC114-7737-4135-BC0A-353ECFA47FA6Q38982780-5171E55B-E245-4508-95AE-4CC4BF491CA0Q39313433-33A6863E-2B4B-44E8-BBAD-7EB019305C18Q41429938-5DD77B3B-7807-43F8-B024-A34544AC4EDBQ41472176-59D08BD4-5D86-4EEC-BF50-1518CC6C7B75Q41635867-01CDBE4E-7D07-4ABA-BA37-8562C334637DQ41872607-7EAFFE25-C1A2-45BB-9CFD-1B7F1F22F971Q43186166-D72C873D-94A9-430C-85AD-C9A420A607CCQ47280331-C31EBD8D-E1D7-4023-85BD-44E699CC5510Q47854701-419F7B14-3CEE-41A8-9EAA-BCE2863E764FQ50236420-357B18D3-0A70-45CA-AA60-05966B13990CQ51347381-CDFFDEAC-EA43-43AE-8F79-A87B626A2E41
P2860
Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Genetically engineered mesench ...... eutic for Huntington's disease
@ast
Genetically engineered mesench ...... eutic for Huntington's disease
@en
type
label
Genetically engineered mesench ...... eutic for Huntington's disease
@ast
Genetically engineered mesench ...... eutic for Huntington's disease
@en
prefLabel
Genetically engineered mesench ...... eutic for Huntington's disease
@ast
Genetically engineered mesench ...... eutic for Huntington's disease
@en
P2093
P2860
P921
P1476
Genetically engineered mesench ...... eutic for Huntington's disease
@en
P2093
Amal Kambal
Gaela-Marie Mitchell
Gary Dunbar
Geralyn Annett
Gerhard Bauer
Heather Stewart
Hyun Sook Kim
Jeannine McGee
Jeremy Tempkin
Kari Pollock
P2860
P2888
P356
10.1007/S12035-011-8219-8
P50
P577
2011-12-09T00:00:00Z